Business · 13/04/2022Updated: 10/17/2026 · 1 min read
Secura Bio, Inc. Seeks FDA Withdrawal of COPIKTRA Approval for Relapsed or Refractory Follicular Lymphoma
Summary
The FDA is withdrawing approval of COPIKTRA (duvelisib) for treating relapsed or refractory follicular lymphoma, following Secura Bio, Inc.'s voluntary request, which waives its right to a hearing